Extracellular nampt is a novel therapeutic target in chorioamnionitis-related prematurity (CHORP)
Ended Project Grant Awarded Last action
- Award ID
- R41HD101202
- Recipient
-
Aqualung Therapeutics, Corp UEI MKDKZ3ZZ99A2
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $265,096
Award facts
- Assistance listing
- 93.865 Child Health and Human Development Extramural Research
- Completion date
- Place of performance
- Arizona, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $265,096 |
Quick answers
Who received award R41HD101202?
R41HD101202 was awarded to Aqualung Therapeutics, Corp by National Institute of Child Health and Human Development (National Institutes of Health) on September 18, 2020.
How much is award R41HD101202 worth?
$265,096 has been obligated on R41HD101202.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award